vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and Xometry, Inc. (XMTR). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $192.4M, roughly 1.1× Xometry, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs -4.5%, a 61.9% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $-5.9M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
Xometry is an online marketplace for sourcing on-demand manufactured parts for prototyping and large-scale production.
IDYA vs XMTR — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $192.4M |
| Net Profit | $119.2M | $-8.6M |
| Gross Margin | — | 39.1% |
| Operating Margin | 52.2% | -4.6% |
| Net Margin | 57.4% | -4.5% |
| Revenue YoY | — | 29.5% |
| Net Profit YoY | 330.1% | 12.7% |
| EPS (diluted) | $1.33 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $192.4M | ||
| Q3 25 | $207.8M | $180.7M | ||
| Q2 25 | — | $162.5M | ||
| Q1 25 | — | $151.0M | ||
| Q4 24 | — | $148.5M | ||
| Q3 24 | $0 | $141.7M | ||
| Q2 24 | $0 | $132.6M | ||
| Q1 24 | $0 | $122.7M |
| Q4 25 | — | $-8.6M | ||
| Q3 25 | $119.2M | $-11.6M | ||
| Q2 25 | — | $-26.4M | ||
| Q1 25 | — | $-15.1M | ||
| Q4 24 | — | $-9.9M | ||
| Q3 24 | $-51.8M | $-10.2M | ||
| Q2 24 | $-52.8M | $-13.7M | ||
| Q1 24 | $-39.6M | $-16.6M |
| Q4 25 | — | 39.1% | ||
| Q3 25 | — | 39.9% | ||
| Q2 25 | — | 40.1% | ||
| Q1 25 | — | 37.3% | ||
| Q4 24 | — | 39.7% | ||
| Q3 24 | — | 39.4% | ||
| Q2 24 | — | 39.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | — | -4.6% | ||
| Q3 25 | 52.2% | -6.1% | ||
| Q2 25 | — | -6.3% | ||
| Q1 25 | — | -10.2% | ||
| Q4 24 | — | -7.8% | ||
| Q3 24 | — | -8.1% | ||
| Q2 24 | — | -11.5% | ||
| Q1 24 | — | -14.6% |
| Q4 25 | — | -4.5% | ||
| Q3 25 | 57.4% | -6.4% | ||
| Q2 25 | — | -16.3% | ||
| Q1 25 | — | -10.0% | ||
| Q4 24 | — | -6.7% | ||
| Q3 24 | — | -7.2% | ||
| Q2 24 | — | -10.3% | ||
| Q1 24 | — | -13.5% |
| Q4 25 | — | — | ||
| Q3 25 | $1.33 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.60 | — | ||
| Q2 24 | $-0.68 | — | ||
| Q1 24 | $-0.53 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $219.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $275.6M |
| Total Assets | $1.2B | $703.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $219.1M | ||
| Q3 25 | $786.9M | $224.5M | ||
| Q2 25 | — | $225.8M | ||
| Q1 25 | — | $231.4M | ||
| Q4 24 | — | $239.8M | ||
| Q3 24 | $920.0M | $234.0M | ||
| Q2 24 | $701.7M | $240.9M | ||
| Q1 24 | $698.8M | $253.8M |
| Q4 25 | — | $275.6M | ||
| Q3 25 | $1.1B | $272.0M | ||
| Q2 25 | — | $270.4M | ||
| Q1 25 | — | $309.9M | ||
| Q4 24 | — | $314.5M | ||
| Q3 24 | $1.2B | $315.2M | ||
| Q2 24 | $931.7M | $315.8M | ||
| Q1 24 | $935.3M | $320.4M |
| Q4 25 | — | $703.7M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | — | $687.0M | ||
| Q1 25 | — | $690.1M | ||
| Q4 24 | — | $680.1M | ||
| Q3 24 | $1.2B | $678.2M | ||
| Q2 24 | $973.7M | $678.6M | ||
| Q1 24 | $961.5M | $692.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $4.4M |
| Free Cash FlowOCF − Capex | $142.2M | $-5.9M |
| FCF MarginFCF / Revenue | 68.4% | -3.0% |
| Capex IntensityCapex / Revenue | 0.0% | 5.3% |
| Cash ConversionOCF / Net Profit | 1.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | $-24.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.4M | ||
| Q3 25 | $142.2M | $5.8M | ||
| Q2 25 | — | $-427.0K | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | — | $9.1M | ||
| Q3 24 | $-49.2M | $-3.6M | ||
| Q2 24 | $-32.9M | $-9.1M | ||
| Q1 24 | $-43.8M | $-11.7M |
| Q4 25 | — | $-5.9M | ||
| Q3 25 | $142.2M | $-1.7M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $-9.2M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $-49.7M | $-8.4M | ||
| Q2 24 | $-33.9M | $-13.5M | ||
| Q1 24 | $-45.1M | $-16.1M |
| Q4 25 | — | -3.0% | ||
| Q3 25 | 68.4% | -0.9% | ||
| Q2 25 | — | -4.5% | ||
| Q1 25 | — | -6.1% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | — | -6.0% | ||
| Q2 24 | — | -10.2% | ||
| Q1 24 | — | -13.1% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | 0.0% | 4.1% | ||
| Q2 25 | — | 4.3% | ||
| Q1 25 | — | 3.6% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 3.3% | ||
| Q1 24 | — | 3.5% |
| Q4 25 | — | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IDYA
Segment breakdown not available.
XMTR
| US | $159.1M | 83% |
| Non Us | $33.3M | 17% |
